HOME >> MEDICINE >> NEWS
Only Eight Percent Of San Francisco HIV-Positive Urban Poor Receive Protease,,Inhibitors

Geneva, Switzerland -- In the first large-scale study of HIV treatment among the urban poor, University of California San Francisco AIDS researchers have found that very few of the HIV-infected poor receive drugs to combat the virus. Of those who do take anti-retroviral drugs, the researchers found a range of how well the patients adhered to their drug-taking regimens, ranging from 24 to 100 percent of prescribed levels. If subjects missed more than 10 percent of their drugs, the HIV treatment became ineffective.

The research project, called the REACH study for "Research in Access to Care in the Homeless," was started in response to concerns that the urban poor may develop resistant strains of HIV as a result of not adhering to their therapy. The UCSF team looked at how many of these people who were HIV-infected received therapy, how well they adhered to their regimens, and how the virus responded. David Bangsberg, MD, MPH, assistant professor of medicine at the UCSF AIDS Program at San Francisco General Hospital, was medical director of the study. He presented the research findings here today (July 1) at the 12th World AIDS Conference.

"This is the first study of anti-retroviral use in a population that makes up a growing portion of the HIV epidemic," said Andrew Moss, PhD, professor of epidemiology and medicine at UCSF and principal investigator. "Poor people are increasingly the main high-risk group for HIV."

Bangsberg said, "Most people think studies can't be done with the homeless because they are hard to keep track of. We found that to be untrue. Of 153 people in the study, we know where 151 of them are now, after more than a year." The UCSF team identified participants for the research project in free food lines, homeless shelters and low-income hotels and tested them for HIV infection. For those HIV-positive people on protease inhibitors, the researchers looked at three measures of adherence: self-report, random pill counts, and a digital
'"/>

Contact: Mitzi Baker
mabaker@itsa.ucsf.edu
(415) 476-2557
University of California - San Francisco
1-Jul-1998


Page: 1 2 3

Related medicine news :

1. Eight New Hartford doctoral fellows in Geriatric Social Work selected
2. Eighty five percent of practice nurses are underestimating the prevalence of insulin resistance in type 2 diabetes patients
3. UCSF And Eight Other Medical Centers Chosen For National Cancer Institutes Pediatric Brain Tumor Consortium
4. Express Scripts 1999 drug trend report: Seniors hit hardest by record 17.4-Percent prescription drug spending increase
5. New Study Finds Blacks Face 38 Percent Higher Stroke Risk
6. Osteoporosis Drug Evista (Raloxifene) Cuts Newly Diagnosed, Invasive Breast Cancer Risk By More Than 60 Percent
7. Study Finds Incidence Of Stroke Over 40 Percent Higher Than Previously Stated Figures
8. Rats Receiving Ginkgo Biloba Learn Quicker, Live 20 Percent Longer Than Controls, UB Study Finds
9. Congress of Neuological Surgeons meets in San Francisco
10. American Academy of Neurology presents 56th Annual Meeting in San Francisco, April 24 - May 1, 2004
11. NIH funds new brain imaging center at San Francisco VA Medical Center

Post Your Comments:
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... 04, 2015 The ability of ... density assessment and help improve breast cancer risk ... accepted for presentation at the European Congress of ... abstracts - eight posters and 2 session presentations ... breast density and quantitative breast imaging software tools ...
(Date:3/4/2015)... March 04, 2015 With the growing influence ... lives of our teens and young adults, combined with the ... and confusing to try to keep up with what kids ... or trend is replaced on a daily basis. , The ... and the slang that is used to discreetly talk about ...
(Date:3/4/2015)... York (PRWEB) March 04, 2015 More ... the cardiovascular risks potentially associated with low testosterone treatments ... (FDA) announced that it will now require manufacturers to ... their risk for heart attacks and strokes. In a ... the agency also stated that it was requiring testosterone ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... AUSTIN, Texas , March 4, 2015 /PRNewswire/ ... Phase II pilot study in patients with moderate ... JAMA Dermatology. The open-label Phase II trial evaluated ... Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). ... and inflammatory cells present in skin lesions. The ...
(Date:3/4/2015)...  Results of the recent study, Results From ... Intra-Operative Positive Margin Detection , were presented as part ... Annual Miami Breast Cancer Conference last week. ... , MD, FACS, Professor of Surgery at the Sackler ... analysis of MarginProbe,s efficiency and accuracy when used consecutively ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
Cached News: